Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

Annals of Oncology

Volumn 14, Issue 8, 2003, Pages 1227-1233

  Reichardt, P ^a   von Minckwitz, G ^b   Thuss Patience, P C ^a   Jonat, W ^c   Kolbl H ^d   Janicke F ^e   Kieback, D G ^f,g   Kuhn, W ^h   Schindler, A E ⁱ   Mohrmann, S ^j   Kaufmann, M ^b   Luck H J ^k  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

^j HEINRICH HEINE UNIVERSITY   (Germany)

^k HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

Capecitabine; Chemotherapy; Clinical trial; Metastatic breast cancer; Phase II; Taxane failure

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CAPECITABINE; DOCETAXEL; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NAUSEA; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0041508753     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg346     Document Type: Article

References (20)

1. Gairard B, Matheson C, Schaffer P et al. Breast cancer: epidemiology, risk factors, screening. Rev Pract 1998; 48: 21-27.
2. Parker SL, Tong T, Bolden S et al. Cancer statistics 1996. CA Cancer J Clin 1996; 65: 5-27.
3. Black RJ, Bray F, Ferlay J et al. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1998. Eur J Cancer 1997; 33: 1075-1107.
4. Perez EA. Current management of metastatic breast cancer. Semin Oncol 1990; 26 (Suppl 12): 110.
5. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281.
6. Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-493.
7. Blum JL, Dièras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast cancer patients. Cancer 2001; 92: 1759-1768.
8. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization 1976.
9. Fumoleau P, Largillier R, Trillet-Lenoir V et al. Capecitabine (Xeloda®) in patients with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes: results of a large phase II study. Proc Am Soc Clin Oncol 2002; 21: 62a (Abstr 247).
10. Miller KD, Rugo H, Cobleigh M et al. Phase III trial of capecitabine plus bevacizumab versus capecitabine alone in women with previously treated metastatic breast cancer. Breast Cancer Res Treat 2002; 76: S37.
11. Talbot D, Moiseyenko V, Van Belle S et al. Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86: 1367-1372.
12. O'Shaughnessy JA, Blum J, Moiseyenko V et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12: 1247-1254.
13. Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favourable profile compared with intravenous 5-FU/leucovorin. Ann Oncol 2002; 13: 566-575.
14. Fazeny B, Zifko U, Meryn S et al. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II study. Cancer Chemother Pharmacol 1996; 39: 150-156.
15. Livingston RB, Ellis GK, Gralow JR et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997; 15: 1395-1400.
16. Zelek L, Barthier S, Delord JP et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001; 92: 2267-2272.
17. Smorenburg C, Bontenbal M, Seynaeve C et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing on both an anthracycline and a taxane. Breast Cancer Res Treat 2001; 66: 83-87.
18. Girre V, Dalenc F, Laurence V et al. Vinorelbine-5-fluorouracil combination as second line chemotherapy in metastatic breast cancer (MBC) after anthracycline-taxanes combination (AT). Ann Oncol 2000; 11 (Suppl 4): 24.
19. Payne SA. A study of the quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 1992; 35: 1505-1509.
20. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-2823.